ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The Company has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The Company's clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.